Category Archives: Events

Latest From Events

U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14

Dent

During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, co- chair of the Congressional Biomedical Research Caucus, joined BIO’s Fritz Bittenbender to discuss the biotech industry in Pennsylvania as well as recent legislative developments affecting the industry. Dent points to the recent omnibus spending agreement which allowed the Food and Drug Administration (FDA) to access user $85 million in user fees sequestered in 2013. These fees are paid to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Immuno Oncology – A 30-year Overnight Success Story

Photo Feb 11, 1 30 16 PM

“It was the Rodney Dangerfield space – couldn’t get no respect” One would never guess those words were used to describe immuno-oncology, a field that has recently bloomed into full-fledged frenzy – with private companies raising unprecedented Series As, impressive data being announced and Science designating the field “Breakthrough of the Year” all in 2013. Yet Dr. Jeffrey Weber, an early member in the “i-onc” research community likened the past several decades of immuno-oncology to Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Economist – Biotechnology: Fever Rising

The-Economist-115x76

After speaking with several attendees and speakers at last week’s BIO CEO & Investor Conference, the Economist featured an article this week about the strong performance of biotech equities recently: AS INVESTORS and executives crammed into a New York ballroom for a conference held this week by the Biotechnology Industry Organisation, the mood was jittery. The previous week eight biotech firms had launched initial public offerings in America, together raising more than $500m. In a discussion Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , ,

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

#BIOCEO14: An Optimistic Outlook for 2014

Panel

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,